367 related articles for article (PubMed ID: 11273770)
1. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
Kuzmin AI; Galenko O; Eisensmith RC
Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
[TBL] [Abstract][Full Text] [Related]
2. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus.
Stein CS; Pemberton JL; van Rooijen N; Davidson BL
Gene Ther; 1998 Apr; 5(4):431-9. PubMed ID: 9614566
[TBL] [Abstract][Full Text] [Related]
3. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector.
Wang Q; Greenburg G; Bunch D; Farson D; Finer MH
Gene Ther; 1997 May; 4(5):393-400. PubMed ID: 9274715
[TBL] [Abstract][Full Text] [Related]
4. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway.
Scaria A; St George JA; Gregory RJ; Noelle RJ; Wadsworth SC; Smith AE; Kaplan JM
Gene Ther; 1997 Jun; 4(6):611-7. PubMed ID: 9231078
[TBL] [Abstract][Full Text] [Related]
5. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
[TBL] [Abstract][Full Text] [Related]
6. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression.
Michou AI; Santoro L; Christ M; Julliard V; Pavirani A; Mehtali M
Gene Ther; 1997 May; 4(5):473-82. PubMed ID: 9274725
[TBL] [Abstract][Full Text] [Related]
8. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys.
Haegel-Kronenberger H; Haanstra K; Ziller-Remy C; Ortiz Buijsse AP; Vermeiren J; Stoeckel F; Van Gool SW; Ceuppens JL; Mehtali M; De Boer M; Jonker M; Boon L
Gene Ther; 2004 Feb; 11(3):241-52. PubMed ID: 14737083
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide.
Bouvet M; Fang B; Ekmekcioglu S; Ji L; Bucana CD; Hamada K; Grimm EA; Roth JA
Gene Ther; 1998 Feb; 5(2):189-95. PubMed ID: 9578838
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated gene transfer into tumors: evaluation of direct readministration of an adenoviral vector into subcutaneous tumors of immunocompetent mice.
Nagao S; Kuriyama S; Okuda H; Tominaga K; Nakatani T; Tsujinoue H; Yoshiji H; Fukui H
Int J Oncol; 2001 Jan; 18(1):57-65. PubMed ID: 11115539
[TBL] [Abstract][Full Text] [Related]
12. Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector.
Ziller C; Stoeckel F; Boon L; Haegel-Kronenberger H
Gene Ther; 2002 May; 9(9):537-46. PubMed ID: 11973629
[TBL] [Abstract][Full Text] [Related]
13. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
[TBL] [Abstract][Full Text] [Related]
14. Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression.
Cao H; Yang T; Li XF; Wu J; Duan C; Coates AL; Hu J
Gene Ther; 2011 Feb; 18(2):173-81. PubMed ID: 20882053
[TBL] [Abstract][Full Text] [Related]
15. Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver.
Alzuguren P; Hervas-Stubbs S; Gonzalez-Aseguinolaza G; Poutou J; Fortes P; Mancheno U; Bunuales M; Olagüe C; Razquin N; Van Rooijen N; Enguita M; Hernandez-Alcoceba R
Liver Int; 2015 Apr; 35(4):1274-89. PubMed ID: 24754307
[TBL] [Abstract][Full Text] [Related]
16. A mouse model of arterial gene transfer: antigen-specific immunity is a minor determinant of the early loss of adenovirus-mediated transgene expression.
Vassalli G; Agah R; Qiao R; Aguilar C; Dichek DA
Circ Res; 1999 Oct; 85(9):e25-32. PubMed ID: 10532959
[TBL] [Abstract][Full Text] [Related]
17. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.
Sarukhan A; Camugli S; Gjata B; von Boehmer H; Danos O; Jooss K
J Virol; 2001 Jan; 75(1):269-77. PubMed ID: 11119597
[TBL] [Abstract][Full Text] [Related]
18. TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus-mediated transgene expression.
Sung RS; Qin L; Bromberg JS
Mol Ther; 2001 May; 3(5 Pt 1):757-67. PubMed ID: 11356080
[TBL] [Abstract][Full Text] [Related]
19. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
[TBL] [Abstract][Full Text] [Related]
20. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors.
Zepeda M; Wilson JM
Gene Ther; 1996 Nov; 3(11):973-9. PubMed ID: 8940637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
